Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
08/10/26	US$4.435	-4.42%	5,087
07/10/26	US$4.640	+7.16%	40,808
06/10/26	US$4.330	-0.69%	6,208
05/10/26	US$4.360	-7.63%	14,294
02/10/26	US$4.720	+3.74%	2,895

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SciSparc Ltd.

Company calendar

Delayed Nasdaq 17:17:38 08/10/2026 BST			5-day change	1st Jan Change
4.435 ^USD	-4.42%		-2.53%	-63.77%

09-30	SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-26	Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026	CI

Market Cap	2.7M 2.41M 2.25M 2.04M 3.84M 261M 3.88M 26.96M 10.55M 133M 10.12M 9.9M 427M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-1.53M -1.37M -1.27M -1.16M -2.18M -148M -2.2M -15.3M -5.98M -75.26M -5.74M -5.62M -242M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	99%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	SPRC	Delayed
CBOE	SPRC	Real-time

09-30	SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-26	Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026	CI
08-16	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.	CI
08-05	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome	CI
07-29	Scisparc Ltd. Announces Establishment of Scientific Advisory Board	CI
06-29	Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding from SciSparc Ltd.	CI
04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-11	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI

SciSparc Ltd. Share Price

Stocks

SPRC

IL0010951403

Pharmaceuticals

Valuation: SciSparc Ltd.

Chart: SciSparc Ltd.

Latest news: SciSparc Ltd.

Press Releases: SciSparc Ltd.

News in other languages: SciSparc Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: SciSparc Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

01:16pm	SciSparc: Subsidiary NeuroThera Labs CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture	AQ
10-07	SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture	GL
09-23	SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations	GL
09-02	SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies	GL
08-31	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial	GL

1 day	-4.42%
1 week	-2.53%
Current month	-6.04%
1 month	-13.04%
3 months	-19.22%
6 months	+29.68%
Current year	-63.77%

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	09/01/2022
Amitay Weiss CEO	Chief Executive Officer	62	20/08/2020
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	07/02/2016

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	09/01/2022
Itschak Shrem CHM	Chairman	79	20/09/2025
Lior Vider BRD	Director/Board Member	50	20/08/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCISPARC LTD.	-4.42%	-2.53%	-88.75%	-99.40%	2.7M
ELI LILLY AND COMPANY	-1.94%	+1.00%	+37.33%	+103.13%	1,060B
JOHNSON & JOHNSON	-0.70%	-0.73%	+35.36%	+61.95%	623B
ABBVIE INC.	+0.16%	+4.56%	+17.53%	+82.26%	480B
MERCK & CO., INC.	-0.37%	-1.15%	+64.53%	+36.03%	352B
ROCHE HOLDING AG	-2.03%	+1.06%	+21.08%	+40.60%	345B
NOVARTIS AG	-1.92%	-0.29%	+10.54%	+33.58%	274B
ASTRAZENECA PLC	-2.36%	-1.16%	-7.14%	+9.54%	249B
AMGEN INC.	-1.51%	-0.15%	+38.03%	+49.76%	223B
GILEAD SCIENCES, INC.	+0.31%	-0.19%	+24.50%	+96.14%	182B
Average	-1.48%	-1.23%	+15.30%	+41.36%	378.8B
Weighted average by Cap.	-1.24%	+0.04%	+30.11%	+67.11%

	2024	2025
Net sales	1.31 1.17 1.09 0.99 1.86 126.49 1.88 13.06 5.11 64.27 4.9 4.8 206.71	0.86 0.76 0.71 0.65 1.22 82.9 1.23 8.56 3.35 42.13 3.21 3.14 135.48
Net income	-6.28M -5.61M -5.24M -4.76M -8.95M -609M -9.04M -62.85M -24.58M -309M -23.59M -23.08M -995M	-12.18M -10.88M -10.15M -9.22M -17.34M -1.18B -17.51M -122M -47.64M -599M -45.73M -44.73M -1.93B
Net Debt	-2.01M -1.8M -1.68M -1.52M -2.86M -195M -2.89M -20.11M -7.87M -98.97M -7.55M -7.39M -318M	-4.22M -3.77M -3.52M -3.2M -6.02M -409M -6.08M -42.26M -16.53M -208M -15.86M -15.52M -669M

1 week	4.2	4.9
1 month	4.2	5.6
Current year	2.98	15.79
1 year	2.98	43.65
3 years	2.98	2,687.56
5 years	2.98	40,049.18
10 years	0.49	41,769.08